Patients age 65 years and older who are hospitalized for the flu can benefit from the use of early antiviral treatment, according to a new report from the CDC. The early use of flu antiviral medications reduces hospital length of stay and risk of needing extended care after discharge.
Patients age 65 years and older who are hospitalized for the flu can benefit from the use of early antiviral treatment, according to a new report from the CDC. The early use of flu antiviral medications reduces hospital length of stay and risk of needing extended care after discharge.
People who are 65 years and older are at a high risk of serious flu complications, and flu antiviral medications work best when they are started early. The results of the study were published in Clinical Infectious Diseases.
The researchers collected data during the 2010-2013 flu seasons from more than 250 hospitals in 13 states on 6593 community-dwelling adults age 65 years and older who were hospitalized for influenza. Overall, 18% of the patients required extended care after being discharged.
Patients who were hospitalized within 2 days of illness onset and treated with antiviral medications within the first 4 days benefited from the early treatment. They had hospitals stays that were substantially shorter than patients who received treatment more than 4 days after illness onset.
The benefit of early treatment had an effect on the need for care after discharge. Patients treated early were 25% to 60% less likely to need extended care after leaving the hospital. Other factors that increased the risk for extended care needs included older age, the presence of neurologic disorders, admission to the intensive care unit, and pneumonia at the time of admission.
"Flu can be extremely serious in older people, leading to hospitalization and in some cases long-term disability," Dan Jernigan, MD, MPH, director of CDC's Influenza Division, said in a statement. “This important study shows that people 65 and older should seek medical care early when they develop flu symptoms.”
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More